Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development
December 11 2017 - 08:00AM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has promoted Dr. Laurent
Humeau to Senior Vice President, Research & Development,
reporting to Dr. J. Joseph Kim, Inovio’s President & CEO. Dr.
Humeau joined Inovio in 2014 as Vice President, R&D.
Dr. Humeau will serve an integral role in
advancing Inovio's portfolio of ASPIRE™ (Antigen SPecific Immune
REsponses) immunotherapies and vaccines covering multiple
therapeutic cancers and infections, supporting clinical study
opportunities, and fostering collaborations with academic partners.
He will provide the technical and strategic leadership for Inovio’s
highly productive R&D group whose activities include:
preclinical development of immunotherapy and vaccine candidates,
immunology and immune monitoring approaches, method development,
product characterization, and analytical development. Under Dr.
Humeau’s leadership in last 4 years, Inovio’s R&D group along
with its collaborators published more than 50 peer-reviewed
pre-clinical and clinical publications and dozens of new patent
filings as well as receiving over $70 million in non-dilutive
grants and contracts from DARPA, NIH, and the Gates Foundation in
support of Inovio’s platform and vaccine development.
Dr. J. Joseph Kim, President and CEO, said, “As
the chief scientist at Inovio, Laurent’s scientific expertise and
his track record of executing our strategic plan make him
well-deserving of this expanded role. Since he joined Inovio, he
has strengthened our R&D discovery and development engine that
is the foundation of our new products and academic
collaborations.”
Prior to Inovio, Dr. Humeau served as a top
R&D leader for several companies, including Chief Scientific
Officer at VIRxSYS Corporation and Senior Director of Translational
Research, Human Therapeutics Division for Intrexon. Dr. Humeau
received his BS and MS in biology from the University Pierre &
Marie Curie, Paris and a PhD in blood cell biology from the
University Denis Diderot.
About Inovio Pharmaceuticals,
Inc.
Inovio is taking immunotherapy to the next level
in the fight against cancer and infectious diseases. We are the
only immunotherapy company that has reported generating T cells in
vivo in high quantity that are fully functional and whose killing
capacity correlates with relevant clinical outcomes with a
favorable safety profile. With an expanding portfolio of immune
therapies, the company is advancing a growing preclinical and
clinical stage product pipeline. Partners and collaborators include
MedImmune, Regeneron, Genentech, The Wistar Institute, University
of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life
Sciences, ApolloBio Corporation, Drexel University, NIH, HIV
Vaccines Trial Network, National Cancer Institute, U.S. Military
HIV Research Program, and Laval University. For more information,
visit www.inovio.com.
This press release contains certain
forward-looking statements relating to our business, including our
plans to develop electroporation-based drug and gene delivery
technologies and DNA vaccines, our expectations regarding our
research and development programs, including the planned initiation
and conduct of clinical trials and the availability and timing of
data from those trials, and the sufficiency of our capital
resources. Actual events or results may differ from the
expectations set forth herein as a result of a number of factors,
including uncertainties inherent in pre-clinical studies, clinical
trials and product development programs, the availability of
funding to support continuing research and studies in an effort to
prove safety and efficacy of electroporation technology as a
delivery mechanism or develop viable DNA vaccines, our ability to
support our pipeline of SynCon® active immunotherapy and vaccine
products, the ability of our collaborators to attain development
and commercial milestones for products we license and product sales
that will enable us to receive future payments and royalties, the
adequacy of our capital resources, the availability or potential
availability of alternative therapies or treatments for the
conditions targeted by the company or its collaborators, including
alternatives that may be more efficacious or cost effective than
any therapy or treatment that the company and its collaborators
hope to develop, issues involving product liability, issues
involving patents and whether they or licenses to them will provide
the company with meaningful protection from others using the
covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
the company can finance or devote other significant resources that
may be necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of the company's technology by
potential corporate or other partners or collaborators, capital
market conditions, the impact of government healthcare proposals
and other factors set forth in our Annual Report on Form 10-K for
the year ended December 31, 2016, our Form 10-Q for the
period ended September 30, 2017, and other regulatory filings we
make from time to time. There can be no assurance that any product
candidate in Inovio's pipeline will be successfully developed,
manufactured or commercialized, that final results of clinical
trials will be supportive of regulatory approvals required to
market licensed products, or that any of the forward-looking
information provided herein will be proven accurate.
Forward-looking statements speak only as of the date of this
release, and Inovio undertakes no obligation to update or revise
these statements, except as may be required by law.
CONTACTS:Investors/Media: Jeff Richardson,
Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2023 to Mar 2024